Thus, thefindings of an extensive study showed that EpCAM expression is detected in 48%of human breast cancer cases [95].Similarly to HER2, EpCAM is already employed as a target in monoclonalantibody-based immunotherapy (using Removab). Here, EPCAM is linked to breast cancer.